Lypanosys Ltd – CEO Interview

Lypanosys is a drug development company. The company’s lead compound, LYP-010, is a naturally derived, fatty acid based, product that is being developed as a safe, oral (capsule and oral suspension) product for the treatment of Eczema.

There are currently no products available for convenient, safe and chronic treatment of Eczema and with around 10% of the US population suffering from the disease this is one of the largest unmet market opportunities in dermatology today. The market opportunity has been extensively and independently validated with primary research and peak sales in the US alone are estimated at more than $700m.

The company has an open Investigational New Drug dossier (IND) with the US Food and Drug Agency (FDA), has completed Chemistry, Manufacturing and Controls (CMC) work, toxicology, Phase 1 and Pharmacokinetic studies as well as a pilot Phase 2a study. The Phase 2b study in adults has been agreed by the FDA and approved by a central ethics committee in the US. The centres have been identified and the study is ready to go – pending funding.

Several Pharmaceutical and Dermatology companies have indicated that they would like to license or acquire this product following the successful completion of this study. Comparable deals in Dermatology support a license deal with a total value well in excess of $200m. We expect to be able to deliver the results from this study within 18 months of funding and expect to have agreed a licensing deal or trade sale with a major Pharma or Dermatology company within 2 years of funding.

Please listen to Andrew Turnbull, Director and CEO.